The anticipation of FDA feedback is a critical regulatory milestone for TFF Pharmaceuticals, directly impacting its TFF TAC clinical development plan. Positive feedback could lead to advancements in the clinical trials, potentially boosting investor confidence and the stock price. Conversely, negative feedback could delay development and impact the stock negatively. However, the exact impact will depend on the nature of the FDA's feedback.